161 related articles for article (PubMed ID: 25804718)
1. Effect of 2'-O-[2-[2-(N,N-dimethylamino)ethoxy]ethyl] modification on activity of gapmer antisense oligonucleotides containing 2',4'-constrained 2'-O-ethyl nucleic acid.
Pandey SK; Nowak A; Perkins J; Ferng A; Prakash TP
Bioorg Med Chem Lett; 2015 Apr; 25(8):1688-1691. PubMed ID: 25804718
[TBL] [Abstract][Full Text] [Related]
2. 2'-O-[2-[2-(N,N-dimethylamino)ethoxy]ethyl] modified oligonucleotides: symbiosis of charge interaction factors and stereoelectronic effects.
Prhavc M; Prakash TP; Minasov G; Cook PD; Egli M; Manoharan M
Org Lett; 2003 Jun; 5(12):2017-20. PubMed ID: 12790517
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the effect of 2'-O-methyl, fluoro hexitol, bicyclo and Morpholino nucleic acid modifications on potency of GalNAc conjugated antisense oligonucleotides in mice.
Prakash TP; Yu J; Kinberger GA; Low A; Jackson M; Rigo F; Swayze EE; Seth PP
Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3774-3779. PubMed ID: 30342955
[TBL] [Abstract][Full Text] [Related]
4. Antisense oligonucleotides containing conformationally constrained 2',4'-(N-methoxy)aminomethylene and 2',4'-aminooxymethylene and 2'-O,4'-C-aminomethylene bridged nucleoside analogues show improved potency in animal models.
Prakash TP; Siwkowski A; Allerson CR; Migawa MT; Lee S; Gaus HJ; Black C; Seth PP; Swayze EE; Bhat B
J Med Chem; 2010 Feb; 53(4):1636-50. PubMed ID: 20108935
[TBL] [Abstract][Full Text] [Related]
5. In Vivo Metabolite Profiles of an
Li XQ; Elebring M; Dahlén A; Weidolf L
Drug Metab Dispos; 2023 Oct; 51(10):1350-1361. PubMed ID: 37429729
[TBL] [Abstract][Full Text] [Related]
6. 2'-O-[2-[(N,N-dimethylamino)oxy]ethyl]-modified oligonucleotides inhibit expression of mRNA in vitro and in vivo.
Prakash TP; Johnston JF; Graham MJ; Condon TP; Manoharan M
Nucleic Acids Res; 2004; 32(2):828-33. PubMed ID: 14762210
[TBL] [Abstract][Full Text] [Related]
7. Development of gapmer antisense oligonucleotide with deoxyribonucleic guanidine (DNG) modifications.
Kojima N; Shrestha AR; Akisawa T; Piao H; Kizawa H; Ohmiya Y; Kurita R
Nucleosides Nucleotides Nucleic Acids; 2020; 39(1-3):258-269. PubMed ID: 31556356
[TBL] [Abstract][Full Text] [Related]
8. Comparing in vitro and in vivo activity of 2'-O-[2-(methylamino)-2-oxoethyl]- and 2'-O-methoxyethyl-modified antisense oligonucleotides.
Prakash TP; Kawasaki AM; Wancewicz EV; Shen L; Monia BP; Ross BS; Bhat B; Manoharan M
J Med Chem; 2008 May; 51(9):2766-76. PubMed ID: 18399648
[TBL] [Abstract][Full Text] [Related]
9. Hsp90 protein interacts with phosphorothioate oligonucleotides containing hydrophobic 2'-modifications and enhances antisense activity.
Liang XH; Shen W; Sun H; Kinberger GA; Prakash TP; Nichols JG; Crooke ST
Nucleic Acids Res; 2016 May; 44(8):3892-907. PubMed ID: 26945041
[TBL] [Abstract][Full Text] [Related]
10. Characterization of target mRNA reduction through in situ RNA hybridization in multiple organ systems following systemic antisense treatment in animals.
Hung G; Xiao X; Peralta R; Bhattacharjee G; Murray S; Norris D; Guo S; Monia BP
Nucleic Acid Ther; 2013 Dec; 23(6):369-78. PubMed ID: 24161045
[TBL] [Abstract][Full Text] [Related]
11. Altered Biodistribution and Hepatic Safety Profile of a Gapmer Antisense Oligonucleotide Bearing Guanidine-Bridged Nucleic Acids.
Sasaki T; Hirakawa Y; Yamairi F; Kurita T; Murahashi K; Nishimura H; Iwazaki N; Yasuhara H; Tateoka T; Ohta T; Obika S; Kotera J
Nucleic Acid Ther; 2022 Jun; 32(3):177-184. PubMed ID: 35073217
[TBL] [Abstract][Full Text] [Related]
12. Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice.
Prakash TP; Graham MJ; Yu J; Carty R; Low A; Chappell A; Schmidt K; Zhao C; Aghajan M; Murray HF; Riney S; Booten SL; Murray SF; Gaus H; Crosby J; Lima WF; Guo S; Monia BP; Swayze EE; Seth PP
Nucleic Acids Res; 2014 Jul; 42(13):8796-807. PubMed ID: 24992960
[TBL] [Abstract][Full Text] [Related]
13. Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index.
Shen W; De Hoyos CL; Migawa MT; Vickers TA; Sun H; Low A; Bell TA; Rahdar M; Mukhopadhyay S; Hart CE; Bell M; Riney S; Murray SF; Greenlee S; Crooke RM; Liang XH; Seth PP; Crooke ST
Nat Biotechnol; 2019 Jun; 37(6):640-650. PubMed ID: 31036929
[TBL] [Abstract][Full Text] [Related]
14. Application of 2'-O-(2-N-Methylcarbamoylethyl) Nucleotides in RNase H-Dependent Antisense Oligonucleotides.
Masaki Y; Iriyama Y; Nakajima H; Kuroda Y; Kanaki T; Furukawa S; Sekine M; Seio K
Nucleic Acid Ther; 2018 Oct; 28(5):307-311. PubMed ID: 30020852
[TBL] [Abstract][Full Text] [Related]
15. Understanding the effect of controlling phosphorothioate chirality in the DNA gap on the potency and safety of gapmer antisense oligonucleotides.
Østergaard ME; De Hoyos CL; Wan WB; Shen W; Low A; Berdeja A; Vasquez G; Murray S; Migawa MT; Liang XH; Swayze EE; Crooke ST; Seth PP
Nucleic Acids Res; 2020 Feb; 48(4):1691-1700. PubMed ID: 31980820
[TBL] [Abstract][Full Text] [Related]
16. Solid-phase synthesis of 5'-triantennary N-acetylgalactosamine conjugated antisense oligonucleotides using phosphoramidite chemistry.
Prakash TP; Brad Wan W; Low A; Yu J; Chappell AE; Gaus H; Kinberger GA; Østergaard ME; Migawa MT; Swayze EE; Seth PP
Bioorg Med Chem Lett; 2015 Oct; 25(19):4127-30. PubMed ID: 26299345
[TBL] [Abstract][Full Text] [Related]
17. Short antisense oligonucleotides with novel 2'-4' conformationaly restricted nucleoside analogues show improved potency without increased toxicity in animals.
Seth PP; Siwkowski A; Allerson CR; Vasquez G; Lee S; Prakash TP; Wancewicz EV; Witchell D; Swayze EE
J Med Chem; 2009 Jan; 52(1):10-3. PubMed ID: 19086780
[TBL] [Abstract][Full Text] [Related]
18. Lipid nanoparticles improve activity of single-stranded siRNA and gapmer antisense oligonucleotides in animals.
Prakash TP; Lima WF; Murray HM; Elbashir S; Cantley W; Foster D; Jayaraman M; Chappell AE; Manoharan M; Swayze EE; Crooke ST
ACS Chem Biol; 2013 Jul; 8(7):1402-6. PubMed ID: 23614580
[TBL] [Abstract][Full Text] [Related]
19. Direct comparison of in vivo antisense activity of ENA oligonucleotides targeting PTP1B mRNA with that of 2'-O-(2-methoxy)ethyl-modified oligonucleotides.
Koizumi M; Takagi-Sato M; Okuyama R; Araki K; Sun W; Nakai D; Tsutsumi S; Kawai K
Oligonucleotides; 2006; 16(3):253-62. PubMed ID: 16978088
[TBL] [Abstract][Full Text] [Related]
20. Comparative Characterization of Hepatic Distribution and mRNA Reduction of Antisense Oligonucleotides Conjugated with Triantennary N-Acetyl Galactosamine and Lipophilic Ligands Targeting Apolipoprotein B.
Watanabe A; Nakajima M; Kasuya T; Onishi R; Kitade N; Mayumi K; Ikehara T; Kugimiya A
J Pharmacol Exp Ther; 2016 May; 357(2):320-30. PubMed ID: 26907624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
